170 related articles for article (PubMed ID: 21205463)
1. Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures.
Corrado A; Neve A; Maruotti N; Gaudio A; Marucci A; Cantatore FP
Clin Exp Rheumatol; 2010; 28(6):873-9. PubMed ID: 21205463
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of osteoblast function in vitro by aminobisphosphonates.
Orriss IR; Key ML; Colston KW; Arnett TR
J Cell Biochem; 2009 Jan; 106(1):109-18. PubMed ID: 19003973
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis repressor with caspase recruitment domain enhances survival and promotes osteogenic differentiation of human osteoblast cells under Zoledronate treatment.
Hu L; Han J; Yang X; Wang Y; Pan H; Xu L
Mol Med Rep; 2016 Oct; 14(4):3535-42. PubMed ID: 27573706
[TBL] [Abstract][Full Text] [Related]
4. Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner--a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2.
Koch FP; Merkel C; Al-Nawas B; Smeets R; Ziebart T; Walter C; Wagner W
J Craniomaxillofac Surg; 2011 Dec; 39(8):562-9. PubMed ID: 21030265
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.
Reinholz GG; Getz B; Pederson L; Sanders ES; Subramaniam M; Ingle JN; Spelsberg TC
Cancer Res; 2000 Nov; 60(21):6001-7. PubMed ID: 11085520
[TBL] [Abstract][Full Text] [Related]
6. The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells.
Ishtiaq S; Edwards S; Sankaralingam A; Evans BA; Elford C; Frost ML; Fogelman I; Hampson G
Cytokine; 2015 Feb; 71(2):154-60. PubMed ID: 25461393
[TBL] [Abstract][Full Text] [Related]
7. The effects of zoledronate on the survival and function of human osteoblast-like cells.
Huang KC; Cheng CC; Chuang PY; Yang TY
BMC Musculoskelet Disord; 2015 Nov; 16():355. PubMed ID: 26572124
[TBL] [Abstract][Full Text] [Related]
8. Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects.
Corrado A; Cantatore FP; Grano M; Colucci S
Clin Rheumatol; 2005 Sep; 24(5):527-34. PubMed ID: 16091841
[TBL] [Abstract][Full Text] [Related]
9. Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells.
Gangoiti MV; Cortizo AM; Arnol V; Felice JI; McCarthy AD
Eur J Pharmacol; 2008 Dec; 600(1-3):140-7. PubMed ID: 18973752
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of neridronate on human osteoblastic cell cultures.
Frediani B; Spreafico A; Capperucci C; Chellini F; Gambera D; Ferrata P; Baldi F; Falsetti P; Santucci A; Bocchi L; Marcolongo R
Bone; 2004 Oct; 35(4):859-69. PubMed ID: 15454093
[TBL] [Abstract][Full Text] [Related]
11. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts.
Fromigué O; Body JJ
J Endocrinol Invest; 2002 Jun; 25(6):539-46. PubMed ID: 12109626
[TBL] [Abstract][Full Text] [Related]
13. Effect of low level laser therapy and zoledronate on the viability and ALP activity of Saos-2 cells.
Bayram H; Kenar H; Taşar F; Hasırcı V
Int J Oral Maxillofac Surg; 2013 Jan; 42(1):140-6. PubMed ID: 22571861
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells.
Kaiser T; Teufel I; Geiger K; Vater Y; Aicher WK; Klein G; Fehm T
Breast Cancer Res Treat; 2013 Jul; 140(1):35-48. PubMed ID: 23807419
[TBL] [Abstract][Full Text] [Related]
15. Effects of pamidronate on human alveolar osteoblasts in vitro.
Marolt D; Cozin M; Vunjak-Novakovic G; Cremers S; Landesberg R
J Oral Maxillofac Surg; 2012 May; 70(5):1081-92. PubMed ID: 21856057
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro.
Walter C; Pabst A; Ziebart T; Klein M; Al-Nawas B
Oral Dis; 2011 Mar; 17(2):194-9. PubMed ID: 20796232
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid at subtoxic dose extends osteoblastic stage span of primary human osteoblasts.
Zara S; De Colli M; di Giacomo V; Zizzari VL; Di Nisio C; Di Tore U; Salini V; Gallorini M; Tetè S; Cataldi A
Clin Oral Investig; 2015 Apr; 19(3):601-11. PubMed ID: 25055744
[TBL] [Abstract][Full Text] [Related]
18. Normal and osteoporotic human osteoblast behaviour after 1,25-dihydroxy-vitamin D(3) stimulation.
Maruotti N; Corrado A; Grano M; Colucci S; Cantatore FP
Rheumatol Int; 2009 Apr; 29(6):667-72. PubMed ID: 18989673
[TBL] [Abstract][Full Text] [Related]
19. Osteoanabolic effect of alendronate and zoledronate on bone marrow stromal cells (BMSCs) isolated from aged female osteoporotic patients and its implications for their mode of action in the treatment of age-related bone loss.
Lindtner RA; Tiaden AN; Genelin K; Ebner HL; Manzl C; Klawitter M; Sitte I; von Rechenberg B; Blauth M; Richards PJ
Osteoporos Int; 2014 Mar; 25(3):1151-61. PubMed ID: 23974861
[TBL] [Abstract][Full Text] [Related]
20. Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells.
Wu L; Zhu L; Shi WH; Zhang J; Ma D; Yu B
Eur J Pharmacol; 2009 Jan; 602(1):124-31. PubMed ID: 19000670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
